Iproteos collaborates in a European project to develop an innovative therapeutic strategy against epilepsy

Iproteos is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides: Ernest Giralt, professor from the Department of Organic Chemistry of UB, and Teresa Tarrago, researcher at IRB Barcelona.
Iproteos is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides: Ernest Giralt, professor from the Department of Organic Chemistry of UB, and Teresa Tarrago, researcher at IRB Barcelona.
Research
(11/05/2015)

To design, validate and bring into practice new innovative therapeutic strategies to further the development of a treatment and a diagnostic approach for the management of epilepsy are the main objectives of the European project ECMED (Extracellular Matrix in Epileptogenesis). ECMED will be developed through a public-private consortium, led by the University College London (United Kingdom), which gathers nine public institutions and two biotechnological firms from different European countries. The Catalan biotechnological company Iproteos —a spin-off of the University of Barcelona and the Institute for Research in Biomedicine (IRB Barcelona), headquartered at the Barcelona Science Park (PCB)— is the only Spanish partner of the consortium. The project will benefit from complementary resources and capabilities combining academic knowledge and basic research with applied research and biotechnology.

For further information, please visit the website of the Barcelona Science Park.  
Iproteos is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides: Ernest Giralt, professor from the Department of Organic Chemistry of UB, and Teresa Tarrago, researcher at IRB Barcelona.
Iproteos is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides: Ernest Giralt, professor from the Department of Organic Chemistry of UB, and Teresa Tarrago, researcher at IRB Barcelona.
Research
11/05/2015

To design, validate and bring into practice new innovative therapeutic strategies to further the development of a treatment and a diagnostic approach for the management of epilepsy are the main objectives of the European project ECMED (Extracellular Matrix in Epileptogenesis). ECMED will be developed through a public-private consortium, led by the University College London (United Kingdom), which gathers nine public institutions and two biotechnological firms from different European countries. The Catalan biotechnological company Iproteos —a spin-off of the University of Barcelona and the Institute for Research in Biomedicine (IRB Barcelona), headquartered at the Barcelona Science Park (PCB)— is the only Spanish partner of the consortium. The project will benefit from complementary resources and capabilities combining academic knowledge and basic research with applied research and biotechnology.

For further information, please visit the website of the Barcelona Science Park.